Evidence map›Paper›PMID 41757559›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Loss of VMP1 Impairs Tight Junction Recycling and Aggravates Intestinal Barrier Dysfunction in Inflammatory Bowel Disease.

Jiawei Zhao, Jianjun Zou, Chen Zhou, Yingui Wang, Yiman Liu, Yanqing Zhou, Yuxiang Wang, Xinyu Zhang, Huishu Yang, Hongjie Yin and 3 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiawei ZhaoState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Jianjun ZouDepartment of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing, P. R. China.
Chen ZhouState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Yingui WangState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Yiman LiuState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Yanqing ZhouState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Yuxiang WangState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Xinyu ZhangState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Huishu YangState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Hongjie YinState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Dongsheng BaiState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Yue ZhaoState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
Na LuState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.ORCID https://orcid.org/0000-0002-4981-5281

Funding

"Double First-Class" University Project CPU2022QZ20National Natural Science Foundation of China 82204409National Natural Science Foundation of China 82373910
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disorder of the gastrointestinal tract. This disease is characterized by a steadily increasing global incidence. Multiple susceptibility genes are implicated in IBD pathogenesis. However, the molecular mechanisms linking epithelial barrier dysfunction to disease progression remain poorly understood. This study performs an integrative analysis of public bulk RNA-seq and single-cell transcriptomic datasets. Experimental validation is conducted using clinical samples. Analyses reveal that vacuole membrane protein 1 (VMP1) is significantly downregulated in IBD. This reduced expression correlates with disease severity. Functional studies demonstrate that VMP1 deficiency in intestinal epithelial cells disrupts tight junction integrity. This loss increases epithelial permeability and exacerbates intestinal inflammation. Mechanistically, VMP1 facilitates the recruitment of CORO1C to late endosomes. This recruitment promotes Retromer-mediated recycling of the tight junction protein Occludin to the plasma membrane. Impairment of this pathway shifts Occludin trafficking toward ESCRT-dependent microautophagic degradation. This shift results in the sustained loss of tight junctions. These findings identify VMP1 as a previously unrecognized regulator of epithelial tight junction recycling and barrier homeostasis. This discovery provides new mechanistic insights into IBD pathogenesis and highlights a promising therapeutic avenue for restoring intestinal barrier function.

Indexed as

Inflammatory Bowel DiseasesIntestinal MucosaMembrane ProteinsTight JunctionsAnimalsEpithelial CellsHumansIntestinal Barrier FunctionMiceOccludinMembrane ProteinsOccludinIBDoccludinrecyclingtight junctionVMP1

Identifiers

PMID41757559
PMCPMC13137792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.